Status:
COMPLETED
Oral Zinc Therapy for the Prevention of Mucositis
Lead Sponsor:
Sheba Medical Center
Conditions:
Mucositis
Eligibility:
All Genders
18-70 years
Phase:
PHASE4
Brief Summary
Zinc is an intracellular mineral with important enzymatic cofactor activities for cell membrane stability, DNA and RNA structure. Zinc deficiency is associated with delayed wound healing and immune dy...
Detailed Description
Patients candidate for High dose chemotherapy with stem cell support for the diagnosis of relapsed/resistant Hodgkins or NHL or MM will be screened for enrollment in the study. Patients will be rando...
Eligibility Criteria
Inclusion
- Patients undergoing high dose chemotherapy with stem cell support for relapsed or resistant Hodgkins or NHL (treated with BEAM protocol) or MM (treated with high dose melphalan).
- ECOG performance less than or equal to 2
- Adequate renal and hepatic function
Exclusion
- Presence of any other active malignancy other than BCC of the skin
Key Trial Info
Start Date :
April 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2008
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00449592
Start Date
April 1 2007
End Date
September 1 2008
Last Update
October 3 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Division of Hematology and Bone Marrow Transplantation, Sheba Medical Center
Ramat Gan, Israel